Search research articles
Contact Us
Filters
Showing results (51-60 of 58) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 58 results.
The Prostate
|
February 15, 2001
Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells
M Aalamian, G Pirtskhalaishvili, A Nunez, et al.
European Urology
|
June 12, 1999
Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics
M Graefen, J Noldus, U Pichlmeier, et al.
The Journal of Urology
|
July 1, 1990
Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients
H Huland, G Klöppel, I Feddersen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 1996
Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects
J Lorenz, K Wilhelm, M Kessler, et al.
The Journal of Urology
|
December 1, 1991
Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder
E Huland, H Huland, T Meier, et al.
European Urology
|
February 27, 2001
Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder
M G Friedrich, S Riethdorf, A Erbersdobler, et al.
British Journal of Cancer
|
August 16, 2006
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
J Atzpodien, H Kirchner, U Rebmann, et al.
Folia Biologica
|
December 19, 2003
Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study
E Huland, A Burger, J Fleischer, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 58) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 58 results.
The Prostate
|
February 15, 2001
Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells
M Aalamian, G Pirtskhalaishvili, A Nunez, et al.
European Urology
|
June 12, 1999
Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics
M Graefen, J Noldus, U Pichlmeier, et al.
The Journal of Urology
|
July 1, 1990
Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients
H Huland, G Klöppel, I Feddersen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 1996
Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects
J Lorenz, K Wilhelm, M Kessler, et al.
The Journal of Urology
|
December 1, 1991
Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder
E Huland, H Huland, T Meier, et al.
European Urology
|
February 27, 2001
Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder
M G Friedrich, S Riethdorf, A Erbersdobler, et al.
British Journal of Cancer
|
August 16, 2006
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
J Atzpodien, H Kirchner, U Rebmann, et al.
Folia Biologica
|
December 19, 2003
Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study
E Huland, A Burger, J Fleischer, et al.
Page
of 6